Role of RhoA in small AAA growth
RhoA 在小 AAA 生长中的作用
基本信息
- 批准号:10295147
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-10-01 至 2023-09-30
- 项目状态:已结题
- 来源:
- 关键词:AbdomenAbdominal Aortic AneurysmAddressAdhesionsAgeAneurysmAnimal ModelAortaBiological AssayBiological MarkersBloodBlood VesselsCaliberCaringCell CountClinicalClinical TrialsClinical assessmentsDataDiagnosisDiseaseEarly DiagnosisElastinEndothelial CellsEndotheliumEnzyme-Linked Immunosorbent AssayEvaluationFailureFeasibility StudiesFutureGoalsGrowthHumanIn VitroInfiltrationInjuryLeadLeukocytesLifeLipopolysaccharidesMatrix MetalloproteinasesMeasurementMeasuresMediatingMedicalMethodsMusNatural HistoryOperative Surgical ProceduresPathologyPatientsPermeabilityPharmacologyPlayPreventionProcessProteinsResearch PriorityRiskRisk AssessmentRisk FactorsRoleRuptureRuptured Abdominal Aortic AneurysmSerumSmooth Muscle MyocytesStainsSudden DeathSurgeonTestingTimeTissuesTransferaseVascular DiseasesVeteransWomanbaseclinical riskexoenzymefasudilfollow-uphuman subjecthuman tissueimaging studyinhibitorinnovationlarge datasetsmenmonocytemouse modelnovelnovel therapeuticspopulation basedpredictive markerpreventpreventable deathprospectiverepairedrhoA GTP-Binding Proteinscreeningtranslational studytreatment strategy
项目摘要
Project Summary/Abstract
An abdominal aortic aneurysm (AAA) is a vascular condition where a major blood vessel in the body can
degenerate, balloon in size leading to ultimate rupture and sudden death. Currently, an AAA is identified through
imaging studies performed as part of a screening study or incidentally when evaluating for other abdominal
pathology. Given that the most important clinical parameter in predicting rupture is the maximal aortic diameter,
a normal aorta of 2.0 cm or less requires no further evaluation, whereas a large aorta >5.5 cm in men and >5.0
cm in women requires surgery. Based upon a large VA population based prospective analysis, 20% of veterans
with small aortas (3.0-5.4 cm) will grow rapidly and may pose a threat to the life of the veteran. Unfortunately,
we do not know which small AAAs will grow rapidly, others slowly, and still others not at all. Failure to identify
rapidly growing small AAAs will lead to a certain but preventable death. Thus, there is a critical need to develop
predictive markers for rapidly growing small AAAs so that surgery can be performed timely.
The medical management of small AAA is one of the top research priorities in the care of the Veterans with
vascular disease. We hope to establish our central hypothesis that RhoA mediated monocyte adhesion to the
aortic endothelium leads to endothelial barrier injury, subsequent monocyte transmigration, increased aortic wall
destruction, and ultimate small AAA growth. This hypothesis will be tested by the following specific aims: 1) To
determine whether the activation of RhoA in monocytes from Veteran subjects with a growing small AAA
will lead to increased monocyte adhesion, and endothelial barrier injury, 2) To determine whether
monocyte RhoA plays a causal role in AAA formation in the animal model, 3) To determine whether high
RhoA protein activity isolated in the monocytes from Veteran subjects with small AAA will predict the
growth of the small AAA (>0.1 cm/year). Current studies have shown the possibility of RhoA as a biomarker
for disease in both AAA formation and growth. RhoA and monocyte activity were identified to be highly expressed
in both the serum and aortic tissue from subjects with AAA compared to age-matched controls, The role of RhoA
in comparing human subjects with growing AAA or stable AAA has yet to be elucidated. To date, there is a lack
of translatability of the data obtained from tissue in human subjects (late in the disease process) or findings from
animal models to the human patient with small AAAs. The innovation of this project is the connection between
the use of RhoA and monocyte activity into an overarching mechanism of biomarkers, leading to future novel
therapies to control small AAA growth. This is a translational study using human Veteran subjects with the readily
available 1,169 veterans identified with small AAAs (3.0-5.4 cm) collected over a 10-year period to make the
completion of the proposed study feasible. Ultimately, we hope that the data collected will open the possibility of
identifying approaches to both predicting and limiting small AAA growth.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhenheng Guo其他文献
Zhenheng Guo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhenheng Guo', 18)}}的其他基金
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis
iPLA2 作为血管炎症、新内膜形成和再狭窄的靶标
- 批准号:
8967092 - 财政年份:2014
- 资助金额:
-- - 项目类别:
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis
iPLA2 作为血管炎症、新内膜形成和再狭窄的靶标
- 批准号:
9275392 - 财政年份:2014
- 资助金额:
-- - 项目类别:
ROLE OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2BETA IN HIGH GLUCOSE-INDUCED
钙非依赖性磷脂酶 A2β 在高血糖诱导中的作用
- 批准号:
8361445 - 财政年份:2011
- 资助金额:
-- - 项目类别:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
iPLA2 将糖尿病与心血管疾病联系起来的新机制
- 批准号:
7834334 - 财政年份:2009
- 资助金额:
-- - 项目类别:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
iPLA2 将糖尿病与心血管疾病联系起来的新机制
- 批准号:
7766988 - 财政年份:2008
- 资助金额:
-- - 项目类别:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
iPLA2 将糖尿病与心血管疾病联系起来的新机制
- 批准号:
7579014 - 财政年份:2008
- 资助金额:
-- - 项目类别:
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases
iPLA2 将糖尿病与心血管疾病联系起来的新机制
- 批准号:
8236894 - 财政年份:2008
- 资助金额:
-- - 项目类别:
相似海外基金
Establishment of human abdominal aortic aneurysm wall strength prediction model using Ex Vivo Superparamagnetic Iron Oxide–Enhanced Magnetic Resonance Imaging
利用Ex Vivo超顺磁性氧化铁建立人体腹主动脉瘤壁强度预测模型
- 批准号:
23K08226 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Extracellular Vesicle Delivery System for Treatment of Abdominal Aortic Aneurysm
细胞外囊泡递送系统治疗腹主动脉瘤
- 批准号:
10751123 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Vascular smooth muscle cell ferroptosis and abdominal aortic aneurysm
血管平滑肌细胞铁死亡与腹主动脉瘤
- 批准号:
10733477 - 财政年份:2023
- 资助金额:
-- - 项目类别:
I-Corps: A Clinical Decision Support Tool to Manage Abdominal Aortic Aneurysm Patients
I-Corps:管理腹主动脉瘤患者的临床决策支持工具
- 批准号:
2318665 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant
Atherosclerosis drives arterial damage and abdominal aortic aneurysm formation and rupture
动脉粥样硬化导致动脉损伤和腹主动脉瘤形成和破裂
- 批准号:
483212 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Impact of PCSK9 inhibition on abdominal aortic aneurysm pathobiology and growth
PCSK9 抑制对腹主动脉瘤病理学和生长的影响
- 批准号:
10566800 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm
开发基于磷脂的纳米疗法治疗腹主动脉瘤
- 批准号:
10749980 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The Role of Amino Acid Starvation Response Kinase GCN2 in Abdominal Aortic Aneurysm
氨基酸饥饿反应激酶 GCN2 在腹主动脉瘤中的作用
- 批准号:
10584543 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Atherosclerotic process drives arterial damage, abdominal aortic aneurysm formation, and rupture
动脉粥样硬化过程导致动脉损伤、腹主动脉瘤形成和破裂
- 批准号:
477264 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Operating Grants
Endovascular Orifice Detection (EOrD) Device for in situ Fenestration of Abdominal Aortic Aneurysm
用于腹主动脉瘤原位开窗的血管内孔口检测 (EOrD) 装置
- 批准号:
10453104 - 财政年份:2022
- 资助金额:
-- - 项目类别:














{{item.name}}会员




